ONO PHARMA. ADR 1/3 Logo
US6827361030
A2N6NC
OPHLY

ONO PHARMA. ADR 1/3

Loading quotes...

Forecast

Buy
  0
Hold
  0
Sell
  2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2026, ONO PHARMA. ADR 1/3 has already paid €0.0719 in dividends. The last payout was in July.

Financials

In the last quarter, ONO PHARMA. ADR 1/3 had revenue of €651.45M and net profit of €116.35M
(EUR) September 2026
YoY
Revenue 651.45M 14.19%
Gross profit 490.46M 11.53%
Net profit 116.35M 11.72%
EBITDA 201.3M 14.23%

Fundamentals

Metric Value
Market capitalization
€6.52B
Number of shares
1.41B
52-week high/low
€5.22 - €3.83
Dividend yield
3.09%
Dividends TTM
€0.15
Beta
0.14
P/E ratio
15.57
PEG ratio
0.29
P/B ratio
1.33
P/S ratio
2.37

Company profile

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and collaboration agreement with Numab Therapeutics AG and Caris Life Sciences, Inc. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.

Name
ONO PHARMA. ADR 1/3
CEO
Gyo Sagara
Headquarters Osaka, os
Japan
Website
IPO
10/02/2012
Employees 4,206

Ticker symbols

Exchange Symbol
Pnk
OPHLY
München
ON40.MU
🍪

Parqet  uses cookies. Learn more